

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

NDT Pharmaceuticals, Inc.

1207 Lewis AV, Suite C, PMB 3004
Tulsa, OK 74104
1-888-261-9127

<https://www.ndtpharmaceuticals.com>
Email: info@ndtpharmaceuticals.com

SIC Code 8731

September 2025 Quarterly Report

For the Period Ending September 30, 2025 - the "Reporting Period")

Outstanding Shares

The number of shares outstanding of our Common Stock was:

160,004,349 as of September 30, 2025

160,004,349 as of December 31, 2024

Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: No:

Change in Control

Indicate by check mark whether a Change in Control⁴ of the company has occurred during this reporting period: Yes: [X] No: []

On September 05, 2025, Zachary O'Shea becomes Sole Officer and Director of the NDT Pharmaceuticals, Inc. and there was a change in the majority shareholders.

1 Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer and names used by predecessor entities, along with the dates of the name changes.

NONE

Current State and Date of Incorporation or Registration: Oklahoma, 03/21/2025.

Standing in this jurisdiction: (e.g. active, default, inactive): Active

Prior Incorporation Information for the issuer and any predecessors during the past five years:

Nevada until 09/05/2025

Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessors since inception:

NONE

List any stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

On September 05, 2025, NDT Pharmaceuticals Inc. (OTC: NDTP) ("NDTP" or the "Company") completed the acquisition of Good Salt Life, LLC, an Athens, Georgia-based innovator in biosafety and infection control. The transaction closed on Friday, September 5, 2025. Good Salt Life, Inc., a wholly owned subsidiary of NDTP, is a vertically integrated biosafety company that designs, manufactures, and deploys infection control ecosystems combining proprietary hardware, EPA-approved chemistries, and data-driven disinfection protocols. Its solutions serve both animal and human environments across 11 countries and 8 industries, with customers ranging from food producers and hospitals to cruise lines and major sports organizations. Good Salt Life's brand ecosystem spans consumer pet care, home care, cosmetics, antimicrobial chemistry, and cutting edge chemical delivery technology, including products trusted by leading institutions such as Merck Animal Health, United Airlines, Carnival Cruise Line, Marriott, and the NFL.

⁴ "Change in Control" shall mean any events resulting in:

- (i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

Address of the issuer's principal executive office

1207 Lewis AV, Suite C, PMB 3004, Tulsa, OK 74104 - Mailing Address

Address of the issuer's principal place of business:

125 Old Monroe Rd. Athens, GA 30606

[] *Check if principal executive office and principal place of business are the same address:*

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: Yes: If Yes, provide additional details below:

2). Security Information

Transfer Agent

Name: Securities Transfer Corporation
Phone: 469-633-0101
Email: <mailto:stc@stctransfer.com>
Address: 2901 N. Dallas, Pkwy., Suite 380, Plano, TX 75093

Publicly Quoted or Traded Securities:

The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.

Trading symbol:	NDTP
Exact title and class of securities outstanding:	Common Stock
CUSIP:	63948Q105
Par or stated value:	\$0.0001
Total shares authorized:	1,125,000,000 as of date: September 30, 2025
Total shares outstanding:	160,004,349 as of date: September 30, 2025
Total number of shareholders of record:	65 as of date: September 30, 2025

Other classes of authorized or outstanding equity securities that do not have a trading symbol:

The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g., preferred shares that do not have a trading symbol). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.

Exact title and class of the security:	<u>Preferred Series V Preferred Stock</u>
CUSIP (if applicable):	NONE
Par or stated value:	\$0.0001
Total shares authorized:	1 as of Date: September 30, 2025
Total shares outstanding (if applicable):	1 as of Date: September 30, 2025
Total number of shareholders of record (if applicable):	1 as of Date: September 30, 2025

Please provide the above-referenced information for all other classes of authorized or outstanding equity securities.

Security Description:

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1. For common equity, describe any dividend, voting and preemption rights.

All common shares are entitled to vote on a one vote for one share basis for all corporate votes and elections.

2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.

The Holders of the Series V Super Voting Preferred Stock shall be entitled to vote on all matters subject to a vote or written consent of the holders of the Corporation's Common Stock, and on all such matters, the share of Series V Super Voting Preferred Stock shall be entitled to that number of votes equal to the number of votes that all issued and outstanding shares of Common Stock and all other securities of the Corporation are entitled to, as of any such date of determination, on a fully diluted basis, plus Three Hundred Million (300,000,000) votes, it being the intention that the Holder of the Series V Super Voting Preferred Stock shall have effective voting control of the Corporation, on a fully diluted basis. The Holder of the Series V Super Voting Preferred Stock shall vote together with the holders of Common Stock as a single class. The holders of Series V Convertible Preferred Stock shall not be entitled to receive dividends paid on the Corporation's Common Stock, and the holders of the Series V Super Voting Preferred Stock shall not be entitled to receive out of the assets of the Corporation, whether from capital or from earnings available for distribution to its stockholders, any amount available for distribution to common stock holders.

3. Describe any other material rights of common or preferred stockholders.

NONE

4. Describe any material modifications to rights of holders of the company’s securities that have occurred over the reporting period covered by this report.

NONE

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer’s securities in the past two completed fiscal years and any subsequent interim period.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: Yes:[X] (If yes, you must complete the table below)

<p>Shares Outstanding <u>Opening Balance:</u> Date: December: 31, 2023 Common: 117,876,899 Preferred V: 1</p>	<p>*Right-click the rows below and select "Insert" to add rows as needed.</p>
--	---

Date of Transaction	Transaction type (e.g., new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to. ***You must disclose the control person(s) for any entities listed.	Reason for share issuance (e.g. for cash or debt conversion) - OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
<u>01/26/23</u>	<u>New Issuance</u>	<u>15,913,381</u>	Common	<u>\$0.000123</u>	<u>YES</u>	<u>Joseph Passalaqua</u>	<u>Debt Conversion</u>	<u>Restricted</u>	<u>Rule 144</u>
01/26/23	<u>New Issuance</u>	<u>140,000,000</u>	Common	<u>\$0.000123</u>	<u>YES</u>	<u>Joseph Passalaqua</u>	<u>Debt Conversion</u>	<u>Restricted</u>	<u>Rule 144</u>
03/16/23	<u>Cancellation of Shares</u>	<u>140,000,000</u>	Common	<u>\$0.000123</u>	<u>YES</u>	<u>Joseph Passalaqua</u>	<u>Cancellation</u>	<u>Restricted</u>	<u>Rule 144</u>
03/16/23	<u>New Issuance</u>	<u>26,214,069</u>	Common Stock	<u>\$0.000123</u>	<u>YES</u>	<u>Joseph Passalaqua</u>	<u>Debt Conversion</u>	<u>Restricted</u>	<u>Rule 144</u>
Ending Balance: Date: September 30, 2025 Common: 160,004,349 Preferred V: 1									

Example: A company with a fiscal year end of December 31st 2024, in addressing this item for its Annual Report, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2023 through December 31, 2024 pursuant to the tabular format above.

*****Control persons for any entities in the table above must be disclosed in the table or in a footnote here.**

Use the space below to provide any additional details, including footnotes to the table above:

N/A

B. Promissory and Convertible Notes

Indicate by check mark whether there are any outstanding promissory, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities:

No: Yes: (If yes, you must complete the table below)

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder. *** You must disclose the control person(s) for any entities listed.	Reason for Issuance (e.g. Loan, Services, etc.)
N/A	-	-	-	-	-	-	-

*****Control persons for any entities in the table above must be disclosed in the table or in a footnote here.**

Use the space below to provide any additional details, including footnotes to the table above:

NONE

4.) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. Ensure that these descriptions are updated on the Company's Profile on www.OTCMarkets.com.

- A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")
 B.
 C.

The purpose of this section is to provide a clear description of the issuer's current operations for the period ending September 30, 2025. In answering this item, please include the following:

A Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

The Company was incorporated on May 13, 2005, under the laws of the State of Nevada as "Mistral Ventures, Inc." and changed its name on January 24, 2020, to "NDT Pharmaceuticals, Inc." Prior company mineral operations were abandoned in 2008, the Company was revived with the State of Nevada in September of 2019, and in July of 2020 (with an effective date of January 1, 2020), the Company acquired all rights under a Sponsored Research Agreement with the University of Pennsylvania, including rights to use the University's NPC technology described below from Compelling Competitive Advantage, LLC ("CCA"), a Delaware limited liability company. CCA assigned all its rights, title and interests in CCA's Sponsored Research Agreement with

the Trustees of the University of Pennsylvania, and any related trade secrets, technology, know-how, formulations, procedures and/or methodologies (the “Intellectual Property”) to the Company.

On September 5, 2025, the Company closed on its acquisition of Good Salt Life, LLC, an Athens, Georgia-based innovator in biosafety and infection control.

Good Salt Life, LLC is dedicated to promoting vitality through eco-friendly, nature-derived products that support healthier living environments. With a focus on innovation and sustainability, the company offers safe and effective solutions for home, pet, personal care, and animal health. Through strategic partnerships, including collaborations in the B2B animal health sector, Good Salt Life, LLC continues to drive advancements that benefit both people and animals.

D. List any subsidiaries, parent company, or affiliated companies.

Good Salt Life, LLC

E. Describe the issuers’ principal products or services.

Innovative consumer health and wellness solutions.

5). Issuer’s Facilities

The goal of this section is to provide investors with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer. Describe the location of office space, data centers, principal plants, and other property of the issuer and describe the condition of the properties. Specify if the assets, properties, or facilities are owned or leased and the terms of their leases. If the issuer does not have complete ownership or control of the property, describe the limitations on the ownership.

The Main office is currently located at 125 Old Monroe Rd., Athens, GA, 30606; The Company leases a 41,000 Sq. Ft. facility as of April 15, 2024. The lease is payment is \$17,170 per month, terminating on September 14, 2026. The Company is also liable for real estate taxes and all other expenses relative to the property.

6). All Officers, Directors, and Control Persons of the Company

Using the table below, please provide information, as of the period end date of this report, regarding all officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, list all individuals or entities controlling 5% or more of any class of the issuer’s securities.

If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.

Names of All Officers, Directors, and Control Persons	Affiliation with Company (e.g. Officer Title /Director/Owner of 5% or more)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Names of control person(s) if a corporate entity
Zachary O'Shea	Sole Officer/Director	Athens, GA	-0-	n/a	0%	n/a
Edward J. Mathias	>5%	NYC, NY	17,600,000	Common	12%	n/a
James B. Hovis	>5%	Old Brookville, NY	14,600,000	Common	9.92%	n/a
Lawrence K. Kubin	>5%	Oakton, VA	11,800,000	Common	8.02%	n/a
Stuart J. Yarborough Family Trust	>5%	Daniel Island, SC	10,670,400	Common	7.25%	Stuart J. Yarborough, Executor
John J. Morrissey	>5%	Falls Church, VA	9,960,000	Common	6.7%	n/a
Konorobi Interactive, LLC	>5%	Orlando, FL	7,500,000	Common	5.1%	Kathy Hazelwood, Managing Director
Kinetixx, Inc.	>5%	Ft. Lauderdale, FL	6,666,667	Preferred	66%	John Barrett, CEO Gretchen Privett, CFO
John Barrett Trust	>5%	Ft. Lauderdale, FL	3,085,309	Preferred	30.85%	John Barrett, Executor

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, log in to www.OTCIQ.com to update your company profile.

7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

NONE

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

NONE

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

NONE

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

NONE

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

NONE

6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

NONE

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

NONE

8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed. Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, update your company profile.

Securities Counsel (must include Counsel preparing Attorney Letters).

Securities Lawyer

Name: Richard Jones, Esq.
Address 1: 750 Hammond Drive,
Address 2: Bldg. 12, Suite 100
Phone: 770-804-0500
Email: jones@corplaw.net

Accountant or Auditor

Name: _____
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

Investor Relations

Name: _____
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

All other means of Investor Communication:

X (Twitter): _____
Discord: _____
LinkedIn: _____
Facebook: _____
[Other] <https://www.ndtpharmaceuticals.com>
Email: info@ndtpharmaceuticals.com/

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement.** This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: _____
Firm: _____
Nature of Services: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

9) Disclosure & Financial Information

A. This Disclosure Statement was prepared by (name of individual):

Name: **Zachary O'Shea**
Title: **Sole Officer/Director**
Relationship to Issuer: **Officer/Director**

B. The following financial statements were prepared in accordance with:

IFRS
 U.S. GAAP

C. The following financial statements were prepared by (name of individual):

Name: **Zachary O'Shea**
Title: **Sole Officer/Director**
Relationship to Issuer: **Officer/Director**

Describe the qualifications of the person or persons who prepared the financial statements:⁵

Mr. O'Shea has degree in business and has over 15 years of experience in business operations and analyzing financial statements for companies.

⁵ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

Provide the following qualifying financial statements: **(On Pages F-1 to F-8 at the end of the document)**

- Audit letter, if audited;
- Balance Sheet;
- Statement of Income;
- Statement of Cash Flows;
- Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- Financial Notes

Financial Statement Requirements:

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be “machine readable”. Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Zack O'Shea certify that:

1. I have reviewed this Disclosure Statement for NDT Pharmaceuticals, Inc.
2. Based on my knowledge, this amended disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this amended disclosure statement.

12/09/25 [Date]

/s/ Zachary O'Shea - Chief Executive Officer

Principal Financial Officer:

I, Zachary O'Shea certify that:

1. I have reviewed this Amended Disclosure Statement for NDT Pharmaceuticals, Inc.
2. Based on my knowledge, this amended disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this amended disclosure statement.

12/09/2025 [Date]

/s/ Zachary O'Shea - Acting Chief Financial Officer

NDT PHARMACUTICALS, INC.

INDEX TO FINANCIAL STATEMENTS

FINANCIAL REPORTS

At

September 30, 2025

INDEX TO FINANCIAL STATEMENTS

Condensed Balance Sheets at September 30, 2025 Unaudited and December 31, 2024	F-2
Condensed Statements of Operations for the Three and Nine Months Ended September 30, 2025 and 2024 - Unaudited	F-3
Condensed Statements of Cash Flows for the Three and Nine Months Ended September 30, 2025 and 2024 - Unaudited	F-4
Condensed Statements of Stockholders' Equity for the Three and Nine Months Ended September 30, 2025 and 2024-Unaudited	F-5-6
Notes to the Condensed Unaudited Financial Statements	F-7-9

NDT PHARMACUTICALS, INC.
CONDENSED BALANCE SHEET
(UNAUDITED)
September 30, 2025

	September 30 ,	December 31,
	2025	2024
ASSETS		
CURRENT ASSETS		
Cash and cash equivalents	\$ 647	\$ 647
Prepaid expenses	\$ 1,500	\$ -
Total current assets	\$ 2,147	\$ 647
Other Assets		
Account Receivables	\$ 142,325	\$ 142,325
Total other assets	\$ 142,325	\$ 142,325
TOTAL ASSETS	\$ 144,472	\$ 142,972
LIABILITIES AND STOCKHOLDERS' DEFICIT		
CURRENT LIABILITIES		
Accounts Payable and Accrued Liabilities	\$ 14,813	\$ 12,781
Accounts Payable - related parties	\$ 61,728	\$ 45,709
Total current liabilities	\$ 76,541	\$ 58,490
Total liabilities	\$ 76,541	\$ 58,490
STOCKHOLDERS' EQUITY		
Common stock		
Authorized: 1,125,000,000 common shares,\$0.0001 par value, 160,004,349 and 160,004,349 issued and outstanding, respectively	\$ 16,000	\$ 16,000
Additional paid-in capital	\$ 191,966	\$ 191,966
Accumulated deficit	\$ (138,735)	\$ (123,484)
Total Stockholders' Equity	\$ 69,231	\$ 84,482
TOTAL LIABILITIES AND STOCKHOLDERS' DEFECIT	\$ 144,472	\$ 142,972

The accompanying notes are an integral part of these condensed financial statements

NDT PHARMACEUTICALS, INC.
CONDENSED STATEMENTS OF OPERATIONS - UNAUDITED
Three and Nine Month Ended June 30, 2025 and 2024

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Sales	\$ -	\$ -	\$ -	\$ -
Cost of Sales	-	-	-	-
Gross Profit	\$ -	\$ -	\$ -	\$ -
Operating Expenses				
General and Administrative	\$ 3,225	\$ 2,200	\$ 6,219	\$ 13,866
Professional Fees	\$ 6,000	\$ -	\$ 6,000	\$ -
Total Expenses	\$ 9,225	\$ 2,200	\$ 12,219	\$ 13,866
Net Income (Loss) for the Period	\$(9,225)	\$(2,200)	\$(12,219)	\$(13,866)
Weighted Average Number of Common Shares - Basic and Diluted	160,004,349	160,004,349	160,004,349	160,004,349
Net Loss for the Period Per Common Shares - Basic and Diluted	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

NDT PHARMACEUTICALS, INC.
Condensed Statements of Cash Flows
For the Nine Months Ended September 30, 2025 and 2024
(UNAUDITED)

	September 30, 2025	September 30, 2024
CASH FLOWS FROM OPERATING ACTIVITIES		
Net Income (loss)	\$ (12,219)	\$ (13,886)
Non-Cash Adjustments:		
Stock issued against debt	-	-
Changes in operating assets and liabilities:		
Prepaid expenses and other current assets	\$ (1,500)	\$ -
Accounts payable and accrued liabilities	\$ 2,032	\$ 1,888
<i>Net cash Provided by (used in) operating activities</i>	<i>\$ (11,687)</i>	<i>\$ (11,998)</i>
Cash flows Provided by Financing Activities		
Proceeds of loan from sponsors	\$ 11,687	\$ 11,998
Net cash provided by Financing Activities	\$ 11,687	\$ 11,998
CHANGE IN CASH AND CASH EQUIVALENTS	\$ -	\$ -
<i>Cash and cash equivalents at beginning of Period</i>	<i>\$ 647</i>	<i>\$ 647</i>
<i>Cash and cash equivalents at end of Period</i>	<i>\$ 647</i>	<i>\$ 647</i>

The accompanying notes are an integral part of these condensed financial statements

NDT PHARMACEUTICALS, INC.
Condensed Statements of Deficit
For the Three and Nine Months Ended September 30, 2025 and 2024
(UNAUDITED)

	Common Stock Shares	Amount	Additional Paid-in Capital	Accumulated Income/(Deficit)	Total Equity (Deficit)
Balance - 01/01/2024	160,004,349	\$ 16,000	\$191,966	\$(106,793)	\$101,173
Net Loss	-	-	-	(1,520)	(1,520)
Balance - 03/31/2024	160,004,349	\$ 16,000	\$191,966	\$(108,313)	\$99,653
Net Loss	-	-	-	(10,166)	(10,166)
Balance - 06/30/2024	160,004,349	\$ 16,000	\$ 191,966	\$(118,479)	\$89,487
Net Loss	-	-	-	(2,220)	(2,200)
Balance - 09/30/2024	160,004,349	\$ 16,000	\$ 191,966	\$(120,679)	\$87,287
Balance - 01/01/2025	160,004,349	\$16,000	\$191,966	\$(123,484)	\$84,482
Net Loss	-	\$ -	\$ -	\$ (3,032)	\$ (3,032)
Balance - 03/31/2025	160,004,349	\$16,000	\$ 191,966	\$(126,516)	\$81,450
Net Loss	-	\$ -	\$ -	\$ (2,994)	\$ (2,994)
Balance - 06/30/2025	160,004,349	\$16,000	\$ 191,966	\$(129,510)	\$78,456
Net Loss	-	\$ -	\$ -	\$ (9,225)	\$ (9,225)
Balance - 09/30/2025	160,004,349	\$16,000	\$ 191,966	\$(138,735)	\$ 69,231

The accompanying notes are an integral part of these condensed financial statements

NOTE 1. ORGANIZATION AND DESCRIPTION OF BUSINESS

The Company was incorporated on May 13, 2005, under the laws of the State of Nevada as “Mistral Ventures, Inc.” and changed its name on January 24, 2020, to “NDT Pharmaceuticals, Inc.” Prior company mineral operations were abandoned in 2008, the Company was revived with the State of Nevada in September of 2019, and in July of 2020 (with an effective date of January 1, 2020), the Company acquired all rights under a Sponsored Research Agreement with the University of Pennsylvania, including rights to use the University’s NPC technology described below from Compelling Competitive Advantage, LLC (“CCA”), a Delaware limited liability company. CCA assigned all its rights, title and interests in CCA’s Sponsored Research Agreement with the Trustees of the University of Pennsylvania, and any related trade secrets, technology, know-how, formulations, procedures and/or methodologies (the “Intellectual Property”) to the Company.

On September 5, 2025, the Company closed on its acquisition of Good Salt Life, LLC, an Athens, Georgia-based innovator in biosafety and infection control.

Good Salt Life, LLC is dedicated to promoting vitality through eco-friendly, nature-derived products that support healthier living environments. With a focus on innovation and sustainability, the company offers safe and effective solutions for home, pet, personal care, and animal health. Through strategic partnerships, including collaborations in the B2B animal health sector, Good Salt Life, LLC continues to drive advancements that benefit both people and animals.

The Company changed its state of incorporation from Nevada to Oklahoma in September 2025

NOTE 2 - GOING CONCERN

The accompanying condensed financial statements have been prepared assuming that the Company will continue as a going concern. The Company has negative working capital, negative cash flows from operations and has an accumulated deficit. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon the Company’s ability to achieve a level of profitability. The Company intends on financing its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at September 30, 2025 and for all periods presented herein, have been made.

CASH AND CASH EQUIVALENTS

All cash, other than held in escrow, is maintained with a major financial institution in the United States. Deposits with this bank may exceed the amount of insurance provided on such deposits. Temporary cash investments with an original maturity of three months or less are considered to be cash equivalents.

INVENTORIES

Inventories are stated at the lower of cost, using an average cost method, or net realizable value.

NET INCOME

Net income (loss) per share is calculated in accordance with FASB ASC 260 topic, "Earnings Per Share." The weighted-average number of common shares outstanding during each period is used to compute basic earning or loss per share. Diluted earnings or loss per share is computed using the weighted average number of shares and diluted potential common shares outstanding. Dilutive potential common shares are additional common shares assumed to be exercised.

Basic net income (loss) per common share is based on the weighted average number of shares of common stock outstanding for the three months periods ending September 30, 2025 and June 30, 2024.

FAIR VALUE ACCOUNTING

As required by the Fair Value Measurements and Disclosures Topic of the FASB ASC 820, fair value is measured based on a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.

The three levels of the fair value hierarchy are described below:

- Level 1 Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
- Level 2 Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;
- Level 3 Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).

SHARE-BASED EXPENSES

FASB ASC 718 "Compensation- Stock Compensation" describes accounting and reporting standards for all share based payment transactions in which employee services are acquired. Transactions include liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights.

Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of FASB ASC 505-50, "Equity -Based Payments to Non-Employees." Measurement of share-based payment transactions with non- employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

NOTE 4 – CAPITAL STOCK

COMMON STOCK

The authorized common stock, par value \$0.0001 is 1,125,000,000 common share. 160,004,349 common shares are issued and outstanding as of September 30, 2025.

PREFERRED STOCK

Preferred Series V Preferred Stock, par value \$0.0001, 1share authorized, and 1 share outstanding as of September 30, 2025.

NOTE 6 – CHANGE IN CONTROL

On September 5, 2025, Mr. Zachary O'Shea became sole officer and director - President, Treasurer, Managing Director, and Company Secretary of the Company.

NOTE 8 - CORPORATE ACTION

On September 05, 2025, NDT Pharmaceuticals Inc. (OTC:NDTP) ("NDTP" or the "Company") completed the acquisition of Good Salt Life, LLC, an Athens, Georgia-based innovator in biosafety and infection control. The transaction closed on Friday, September 5, 2025. Good Salt Life, a wholly owned subsidiary of NDTP, is a vertically integrated biosafety company that designs, manufactures, and deploys infection control ecosystems combining proprietary hardware, EPA-approved chemistries, and data-driven disinfection protocols. Its solutions serve both animal and human environments across 11 countries and 8 industries, with customers ranging from food producers and hospitals to cruise lines and major sports organizations. Good Salt Life's brand ecosystem spans consumer pet care, home care, cosmetics, antimicrobial chemistry, and cutting edge chemical delivery technology, including products trusted by leading institutions such as Merck Animal Health, United Airlines, Carnival Cruise Line, Marriott, and the NFL.

The Company changed its state of incorporation from Nevada to Oklahoma in September 2025;

NOTE 9: SUBSEQUENT EVENT

The Company has analyzed its operations subsequent to July 01, 2025 to the date of November 14, 2025 and has determined that it has no subsequent event(s) to report.